Cell and Gene Outsourcing
-
The Matryoshka Model: The New Face Of Contract Packaging In Pharma
6/4/2025
Contract packaging organizations are the outer layer of the pharmaceutical Matryoshka (the iconic Russian nesting doll): the final form that contains within it a series of intricately crafted parts.
-
Building A Burgeoning Advanced Therapy Infrastructure In The Middle East
6/2/2025
In this conversation, Dr. Boro Dropulić, Executive Director of Caring Cross, shares his perspective on regional challenges, opportunities for innovation, and the role of global partnerships.
-
The Advantages Of Off-The-Shelf GMP iPSCs With A DMF
6/2/2025
Learn how off-the-shelf, GMP-grade iPSC lines with a Drug Master File (DMF) can accelerate cell therapy development, streamline regulatory approval, and reduce time and cost to clinic.
-
ActiCells™ RUO Hypo hiPSCs
6/2/2025
Accelerate your allogeneic development by starting with a hypoimmunogenic iPSC platform reprogrammed from CD34+ cord blood cells.
-
ActiCells™ RUO TARGATT™ Hypo hiPSC Knock-In Kit
6/2/2025
Rapidly advance your allogeneic development with a hypoimmunogenic iPSC platform that has pre-built TARGATT™ large knock-in technology.
-
iPSC Gene Editing Services
6/2/2025
From precise edits to robust expression, get iPSC genome editing done right — from the experienced innovators in gene editing and iPSC technology.
-
Establishing A Versatile Platform For Intensified Lentiviral Vector Manufacturing
6/2/2025
Accelerate access to high-quality, cost-effective lentiviral vectors with our intensified TFDF-based manufacturing platform, delivering multi-fold yield improvements and scalable, space-efficient production.
-
Optimizing AAV8 Capsid Purification With Oversized GOI
6/2/2025
Enhance AAV gene therapy quality and regulatory compliance with our advanced AEX-based purification platform, achieving >90% full capsid purity — even for oversized AAV8 vectors.
-
Optimization Of rAAV Production Using An In-House Suspension HEK293 Cell Line
6/2/2025
Boost rAAV yields and quality while reducing costs with our proprietary HEK293 cell line and scalable, optimized manufacturing platform for gene therapy.
-
Engineering Rep-Cap Plasmids To Enhance AAV Manufacturability, Potency
6/2/2025
Discover how our engineered Rep-Cap plasmids dramatically enhance AAV vector yield, quality, and scalability, offering a powerful, next-generation solution to overcome manufacturing challenges.